Stock Events

Stock Events

Krystal Biotech 

€324.20
77
-€4.90-1.49% Thursday 15:30

Statistics

Day High
322.3
Day Low
322.3
52W High
324.2
52W Low
269.6
Volume
21
Avg. Volume
-
Mkt Cap
9.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q1 2026
Next
1.27
1.37
1.47
1.57
Expected EPS
1.54429671792
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4KB.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abeona Therapeutics
ABEO
Mkt Cap364.77M
Abeona Therapeutics focuses on developing gene and cell therapies for life-threatening diseases, similar to Krystal Biotech's gene therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same innovative treatment space as Krystal Biotech.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Pfizer
PFE
Mkt Cap138.61B
Pfizer, through its acquisition of Bamboo Therapeutics, has ventured into gene therapy, making it a competitor with its vast resources.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals, with its CRISPR and gene editing ventures, represents a broader competitor in the genetic treatment landscape.
Novartis
NVS
Mkt Cap305.1B
Novartis has made significant investments in gene therapy, including the acquisition of AveXis, positioning it as a major player in the field.

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Show more...
CEO
ISIN
US5011471027
WKN
000A2JH2F

Listings

MI
IT
1KRYS.MI
SA
BR
K1YS34.SA
XETRA
DE
4KB.XETRA
STU
DE
4KB.STU

0 Comments

Share your thoughts

FAQ

What is Krystal Biotech stock price today?▼
The current price of 4KB.XETRA is €324.20 EUR — it has decreased by -1.49% in the past 24 hours. Watch Krystal Biotech stock price performance more closely on the chart.
What is Krystal Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Krystal Biotech stocks are traded under the ticker 4KB.XETRA.
What is Krystal Biotech market cap?▼
Today Krystal Biotech has the market capitalization of 9.56B
When is the next Krystal Biotech earnings date?▼
Krystal Biotech is going to release the next earnings report on August 10, 2026.
What were Krystal Biotech earnings last quarter?▼
4KB.XETRA earnings for the last quarter are 1.57 EUR per share, whereas the estimation was 1.27 EUR resulting in a +22.8% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Krystal Biotech located?▼
Krystal Biotech operates in the Other sector.
When did Krystal Biotech complete a stock split?▼
Krystal Biotech has not had any recent stock splits.